{ "@context": "https://schema.org", "@graph": [ { "@type": "LegalCase", "@id": "case-9262", "postId": 9262, "name": "Nano-X Imaging Ltd.", "description": "Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nano-X To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nano-X between March 31, 2025 and April 17, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nano-X Imaging Ltd. (\u201cNano-X\u201d or the \u201cCompany\u201d) (NASDAQ: NNOX) and reminds investors of the August 11, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants overstated purported efficiency gains achieved in Nano-X’s operations, as well as the purported increased demand for its products; (2) in reality, Nano-X’s production and manufacturing operations were poorly aligned with demand for the Company’s products; (3) as a result, Nano-X was experiencing significantly increased operating expenses and cash burn; (4) the foregoing significantly increased the likelihood that Nano-X would be forced to take disruptive remedial measures with respect to its manufacturing operations, entailing significant restructuring and impairment charges; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Lead Plaintiff Deadline: August 11, 2026 \u00a0Call\u00a0Partner Josh Wilson\u00a0at\u00a0877-247-4292\u00a0or\u00a0212-983-9330 (Ext. 1310) Or\u00a0submit your information below\u00a0to learn about your rights.", "identifier": "NNOX", "legal": { "court": "United States District Court for the District of New Jersey", "jurisdiction": "Federal (United States), federal securities laws" }, "classPeriod": { "start": "03/31/2025", "end": "04/17/2026" }, "leadPlaintiffDeadline": "08/11/2026", "caseStatus": { "name": "", "slug": "" }, "practiceArea": { "name": "Securities Litigation", "slug": "securities-litigation" }, "url": "https://faruqilaw.com/case/nano-x-imaging-ltd/", "canonicalUrl": "https://faruqilaw.com/case/nano-x-imaging-ltd/", "datePublished": "2026-06-15T17:12:13+00:00", "dateModified": "2026-06-15T17:12:13+00:00", "associatedOrganization": { "@id": "case-9262-org" }, "legalService": { "@id": "case-9262-legalservice" }, "hasPart": [ { "@id": "case-9262-faq" }, { "@id": "case-9262-press-list" } ], "legalRepresentation": [ { "@id": "case-9262-attorney-516" }, { "@id": "case-9262-attorney-506" } ] }, { "@type": "Organization", "@id": "case-9262-org", "name": "Nano-X Imaging Ltd.", "identifier": "NNOX", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "url": "https://www.nanox.vision/" }, { "@type": "LegalService", "@id": "case-9262-legalservice", "name": "Faruqi & Faruqi, LLP", "url": "https://faruqilaw.com/", "telephone": "+1-212-983-9330", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "address": { "@type": "PostalAddress", "streetAddress": "685 3rd Ave 26th Floor", "addressLocality": "New York", "postalCode": "10017", "addressRegion": "NY", "addressCountry": "US" }, "sameAs": [ "https://faruqilaw.com/", "https://maps.google.com/?cid=3247549158190754383" ] }, { "@type": "Person", "@id": "case-9262-attorney-516", "name": "James M. Wilson, Jr.", "worksFor": { "@id": "case-9262-legalservice" } }, { "@type": "Person", "@id": "case-9262-attorney-506", "name": "Robert W. Killorin", "worksFor": { "@id": "case-9262-legalservice" } }, { "@type": "FAQPage", "@id": "case-9262-faq", "mainEntity": [ { "@type": "Question", "name": "Why is Nano-X Imaging facing a securities class action lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "Investors allege Nano-X Imaging made misleading statements about operational efficiency, product demand, and manufacturing performance." } }, { "@type": "Question", "name": "What are investors claiming about Nano-X\u2019s operational efficiency?", "acceptedAnswer": { "@type": "Answer", "text": "The complaint alleges the company overstated efficiency gains and improvements within its manufacturing operations." } }, { "@type": "Question", "name": "Why is product demand important in the Nano-X lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "Investors claim Nano-X overstated demand for its products, which may have affected expectations for growth and profitability." } }, { "@type": "Question", "name": "What are investors alleging about Nano-X\u2019s manufacturing operations?", "acceptedAnswer": { "@type": "Answer", "text": "The lawsuit claims production levels and manufacturing capacity were not properly aligned with actual customer demand." } }, { "@type": "Question", "name": "How could production-demand misalignment affect Nano-X?", "acceptedAnswer": { "@type": "Answer", "text": "Excess production can increase costs, reduce efficiency, and create pressure on margins and cash flow." } }, { "@type": "Question", "name": "What are investors alleging about Nano-X\u2019s operating expenses?", "acceptedAnswer": { "@type": "Answer", "text": "Plaintiffs claim the company faced significantly higher operating expenses than investors were led to believe." } }, { "@type": "Question", "name": "What is cash burn and why is it mentioned in the Nano-X case?", "acceptedAnswer": { "@type": "Answer", "text": "Cash burn measures how quickly a company spends cash. Investors allege Nano-X\u2019s cash usage was higher than disclosed." } }, { "@type": "Question", "name": "Why are restructuring charges important to Nano-X investors?", "acceptedAnswer": { "@type": "Answer", "text": "Restructuring efforts can lead to significant expenses, operational disruptions, and reduced profitability." } }, { "@type": "Question", "name": "What are impairment charges in the Nano-X lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "Impairment charges are accounting write-downs that may occur when assets lose value or business expectations decline." } }, { "@type": "Question", "name": "What are investors alleging Nano-X failed to disclose?", "acceptedAnswer": { "@type": "Answer", "text": "The complaint claims the company did not fully reveal operational challenges, rising costs, and restructuring risks." } }, { "@type": "Question", "name": "Who may qualify to participate in the Nano-X Imaging class action?", "acceptedAnswer": { "@type": "Answer", "text": "Investors who purchased Nano-X Imaging securities between March 31, 2025 and April 17, 2026 may be eligible if they suffered losses." } }, { "@type": "Question", "name": "What is the deadline to seek lead plaintiff status in the Nano-X lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "Investors seeking appointment as lead plaintiff must file a motion by August 11, 2026." } }, { "@type": "Question", "name": "What is a securities class action lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "A securities class action allows investors to collectively pursue claims against a company for misleading statements or omissions." } }, { "@type": "Question", "name": "What does the term \u201cclass period\u201d mean in a securities lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "The class period is the timeframe during which alleged misleading statements occurred and investors may have purchased securities." } }, { "@type": "Question", "name": "What is a lead plaintiff in a securities class action?", "acceptedAnswer": { "@type": "Answer", "text": "The lead plaintiff is the investor selected by the court to represent the interests of all shareholders and help oversee the litigation." } } ] }, { "@type": "NewsArticle", "@id": "case-9262-press-1", "headline": "Nano-X Imaging (NNOX) Builds Commercial Momentum With Multi-Year Nanox.ARC Deployment Deals", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nano-x-imaging-nnox-builds-062444145.html", "datePublished": "2026-05-12" }, { "@type": "NewsArticle", "@id": "case-9262-press-2", "headline": "Nano-X Imaging (NNOX) Is Down 36.7% After 2025 Losses Deepen And New CFO Joins - Has The Bull Case Changed?", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-nnox/nano-x-imaging/news/nano-x-imaging-nnox-is-down-367-after-2025-losses-deepen-and", "datePublished": "2026-04-23" }, { "@type": "NewsArticle", "@id": "case-9262-press-3", "headline": "Nano-X falls after Q4 miss, CFO transition", "url": "https://seekingalpha.com/news/4576676-nano-x-stock-falls-q4-miss-cfo-change", "datePublished": "2026-04-20" }, { "@type": "NewsArticle", "@id": "case-9262-press-4", "headline": "Nanox Announces Fourth Quarter of 2025 Financial Results and Provides Business Updates", "url": "https://www.globenewswire.com/news-release/2026/04/20/3276960/0/en/nanox-announces-fourth-quarter-of-2025-financial-results-and-provides-business-updates.html", "datePublished": "2026-04-20" }, { "@type": "NewsArticle", "@id": "case-9262-press-5", "headline": "Nanox partners with Meir Medical Center for imaging study", "url": "https://www.investing.com/news/company-news/nanox-partners-with-meir-medical-center-for-imaging-study-93CH-4612715", "datePublished": "2026-04-14" }, { "@type": "ItemList", "@id": "case-9262-press-list", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "@id": "case-9262-press-1" } }, { "@type": "ListItem", "position": 2, "item": { "@id": "case-9262-press-2" } }, { "@type": "ListItem", "position": 3, "item": { "@id": "case-9262-press-3" } }, { "@type": "ListItem", "position": 4, "item": { "@id": "case-9262-press-4" } }, { "@type": "ListItem", "position": 5, "item": { "@id": "case-9262-press-5" } } ] } ] }

Nano-X Imaging Ltd.

Nano-X Imaging Ltd.

Join Action
Case Details
Ticker NNOX
Class Period 03/31/2025 - 04/17/2026
Lead Plaintiff Deadline 08/11/2026
Days Left to Seek Plaintiff
56

If you are a Nano-X Imaging investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nano-X To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Nano-X between March 31, 2025 and April 17, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) and reminds investors of the August 11, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants overstated purported efficiency gains achieved in Nano-X’s operations, as well as the purported increased demand for its products; (2) in reality, Nano-X’s production and manufacturing operations were poorly aligned with demand for the Company’s products; (3) as a result, Nano-X was experiencing significantly increased operating expenses and cash burn; (4) the foregoing significantly increased the likelihood that Nano-X would be forced to take disruptive remedial measures with respect to its manufacturing operations, entailing significant restructuring and impairment charges; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

📞 Lead Plaintiff Deadline: August 11, 2026

💻 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action
Nano-X Imaging Ltd.
1
1
1
1

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Counsel
James M. Wilson, Jr.
jwilson@faruqilaw.com
Phone (212) 983-9330
Fax (212) 983-9331
Robert W. Killorin
rkillorin@faruqilaw.com
Phone (404) 847-0617
Fax (404) 506-9534
Office
New York
685 Third Avenue 26th Floor New York New York 10017
Phone (212) 983-9330
Fax (212) 983-9331

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
Send Us a Message
New York
685 Third Avenue 26th Floor
New York New York 10017
(877) 247-4292 / (212) 983-9330
(212) 983-9331
Los Angeles
1901 Avenue of the Stars Suite 1060
Los Angeles California 90067
(424) 256-2884
(424) 256-2885
Atlanta
3565 Piedmont Road NE Building Four, Suite 380
Atlanta Georgia 30305
(404) 847-0617
(404) 506-9534
Philadelphia
1617 JFK Boulevard, Suite 1550 Philadelphia
Pennsylvania 19103
(215) 277-5770
(215) 277-5771